1. Confidential | 1
Corporate Overview
• Founded 2007 by David Walt (founder of Illumina) and Nicholas Naclerio
• Exclusive licensee of patent portfolio developed by David Walt at Tufts University
• ̴ 50 employees, 15 Ph.D’s
• Expanded to state-of-the-art 20,000 sq. ft. facility April 2012 in Lexington, MA
• Venture-backed by leading life science investors and strategic partners
• Cumulative $47M Raised in Series A, B, C

2. Confidential | 2
Single Molecule Arrays (Simoa) Provide a Digital Advantage
0 pM 10 pM
• Reaction volume = 100 ×10−6 L
• Diffusion = dilution = low sensitivity
• Millions of molecules needed to reach detection limit
• Reaction volume = 50 ×10−15 L (2 billion times smaller), 50 femtoliters
• Diffusion defeated = single molecule resolution = ultimate sensitivity
• One molecule needed to reach detection limit
Simoa (Digital)
0 aM 3.5 aM 350 aM 3.5 fM

3. Confidential | 3
Step 1. Load Consumables
• Kits
• Cuvettes and disposable tips
• Simoa discs
Step 3. Load Samples
• 96 well plates or tubes
Step 2. Menu Setup
• Select assay
• Calibrators and controls
Step 4. Run Samples
Step 5. Data analysis
• First result in 75 min
 Ultra-sensitive with
fully automated
simplicity
 Small sample volumes
 Open platform
(Homebrew for RUO)
 68 test per hour, >500
data points per day
Quanterix Instrument Workflow

4. Confidential | 4
Digital ELISA detects proteins in the fg/mL range
Protein
SiMoA LOD
(pg/mL)
Gold Standard
Assay LOD
(pg/mL)
Sensitivity
Fold
Increase
IL-1b 0.001 0.057 R&D Systems 57
TNF-a 0.003 0.106 R&D Systems 35
GM-CSF 0.003 0.26 R&D Systems 87
p24 0.005 5 OCD 1000
IL-6 0.005 0.039 R&D Systems 8
PSA 0.006 10 Roche/Siemens 1667
Ab42 0.02 50 Innotest 2500
tau 0.02 60 Innotest 3000
IL-1a 0.024 1 R&D Systems 42
GLP-1 0.033 11 Luminex 333
p-tau (181 + 231) 0.04 NA NA ND
IL-5 0.049 0.115 R&D Systems 2
Troponin I 0.05 3 Abbott Architect (HS) 60
p-tau-231 0.05 NA NA ND
p-tau-181 0.1 60 Innotest 600

5. Confidential | 5
Simoa Addresses Many Opportunities That Exist for
High Sensitivity Clinical Diagnostics
Infectious Disease
Inflammatory DiseaseOncology
1 mm3 Tumor
BloodBrain
Endothelial Cells
Neurodegenerative Disease
Prenatal Screening
Cardiovascular Disease
Abnormal/
Rare Protein
Simoa allows blood tests for
neurological disorders
Simoa is world’s most sensitive
troponin test
Simoa is first Immunoassay to
be as sensitive to virus as PCR
Simoa first technology to
quantify effect of anti-TNF-a
drugs on target protein
Simoa shortened time for
detection of cancer recurrence
from years to months

6. Confidential | 6
SimoaTM Benefits
Current Offerings Simoa
Current technologies lack sufficient sensitivity for
many biomarkers
̴ 1000x sensitivity improvement
(femtomolar, 10-15)
Limited dynamic range > 4 logs of dynamic range
Time consuming manual process (3-5 hrs.) Fully automated system – sample in, result out,
save on FTE cost and manual errors
Imprecision High imprecision of results < 10% CVs thanks to digital approach
Large sample size (25-50 microliters) As little at 1 microliter (with dilution)
Acceptable cost/sample Similar costs to current approach, using
conventional reagents
Limited path to Laboratory Developed Tests (LDT)
and IVD
Simoa is very amenable to LDT. Partner in IVD is
bioMerieux